2021
DOI: 10.1016/j.cell.2021.07.029
|View full text |Cite
|
Sign up to set email alerts
|

Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
103
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 127 publications
(105 citation statements)
references
References 100 publications
2
103
0
Order By: Relevance
“…To more directly examine how ILC3s in the MedLNs functionally impact adaptive immunity, we used a mouse model in which ILC3s selectively lack MHC class II by crossing Rorc cre mice and mice with floxed alleles of H2-Ab1 ( Goc et al, 2021 ; Hepworth et al, 2013 , 2015 ; Melo-Gonzalez et al, 2019 ). Following induction of HDM-induced airway inflammation, we identify that this mouse line significantly and selectively targets for MHC class II deletion only in ILC3s, and does not impact MHC class II levels on B cells, cDC subsets, macrophages (Macs), T cells, or ILC2s in the MedLN and lung parenchyma relative to littermate controls ( Figures 2D , 2E , S2A , and S2B ).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…To more directly examine how ILC3s in the MedLNs functionally impact adaptive immunity, we used a mouse model in which ILC3s selectively lack MHC class II by crossing Rorc cre mice and mice with floxed alleles of H2-Ab1 ( Goc et al, 2021 ; Hepworth et al, 2013 , 2015 ; Melo-Gonzalez et al, 2019 ). Following induction of HDM-induced airway inflammation, we identify that this mouse line significantly and selectively targets for MHC class II deletion only in ILC3s, and does not impact MHC class II levels on B cells, cDC subsets, macrophages (Macs), T cells, or ILC2s in the MedLN and lung parenchyma relative to littermate controls ( Figures 2D , 2E , S2A , and S2B ).…”
Section: Resultsmentioning
confidence: 99%
“…These cytokines drive antimicrobial responses that shape the microbiota and protect from invading pathogens ( Ouyang et al, 2008 ; Sonnenberg et al, 2011 ; Zheng et al, 2008 ). Furthermore, ILC3s are major regulators of immunological tolerance to the microbiota and dietary antigens in the intestine, in part through the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or IL-2 that subsequently support regulatory T cell (Treg) homeostasis ( Mortha et al, 2014 ; Zhou et al, 2019 ) or through direct regulation of CD4 + T cells by antigen presentation on major histocompatibility complex class II (MHC class II) ( Goc et al, 2021 ; Hepworth et al, 2013 , 2015 ; Melo-Gonzalez et al, 2019 ; Sonnenberg and Hepworth, 2019 ).…”
Section: Introductionmentioning
confidence: 99%
“…The proportion of ILC subsets differs according to the organ [ 16 ]. ILC transcriptional profile, phenotype and function are heavily influenced by their microenvironment and their phenotypes vary largely from tissue to tissue [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. Genetic fate-mapping in mouse using key ILC features has further confirmed that ILC exhibit substantial plasticity and can modify their phenotype and function to resemble other ILC subsets, depending on the microenvironment signals [ 23 , 24 , 25 , 26 ].…”
Section: Innate Lymphoid Cell Diversity Within Tissuesmentioning
confidence: 99%
“…Data from the literature show that these pro-inflammatory ILC1s derive from ILC3 transformation under the influence of TGF-β and IL-23 [102,103], which are abundant in CRC [104]. ILC3s in CRC were impaired in their frequencies and functions [105].…”
Section: Ilc1 In Cancermentioning
confidence: 99%
“…In addition, in CRC, during the tumor progression, the amount of NKp44 + ILC3s decreases with a concomitant increment in ILC1s and NKp44 − ILC3s [141], thus indicating ILC plasticity [101]; the reduction in NKp44 + ILC3s is also related to tertiary lymphoid structure reduction in CRC [141]. Another study on CRC reported not only an alteration of ILC3s in terms of frequency and plasticity, but also an imbalance with T cells; ILC3s were shown to be protective against CRC; however, their alteration leads to CRC invasion and resistance to immunotherapies because of microbiota changes [105]. In vivo studies demonstrated that in the gut the production of GM-CSF by ILC3s was driven by macrophages that produce IL-1β in response to microbial signals.…”
Section: Ilc3 In Cancermentioning
confidence: 99%